The nuclear export mediator XPO1, also known as CRM1, has gained attention as a critical target in cancer therapy due to its overactivity in various malignancies, including ovarian carcinoma, glioma, osteosarcoma, pancreatic, and cervical cancers. This evidence concerns the gene XPO1 and osteosarcoma.